Roche/Genentech–Hanmi $2.3B License: Deal Structure Breakdown

$190M Upfront: Roche/Genentech Licenses Hanmi's HM17321 in $2.3B Metabolic Peptide Deal

$190 million in upfront cash for a Phase 1 metabolic peptide — that is the price Roche/Genentech paid on August 24, 2026, to secure global licensing rights to Hanmi Pharmaceutical's HM17321. The total deal value reaches $2.3 billion when including $2.1 billion in development, regulatory, and commercial milestones, with royalty tiers left undisclosed. This is one of the largest Phase 1 metabolic licensing transactions of 2026, and it tells you exactly how much Big Pharma is willing to pay to stay competitive in a therapeutic area that has become an arms race. The Hanmi Pharmaceutical Roche/Genentech deal terms set a new benchmark for early-stage peptide assets in metabolic disease.

Deal Structure Breakdown

Let's dissect the economics of the Hanmi Pharmaceutical Roche/Genentech deal structure.

Upfront-to-TDV Ratio: 8.3%

The upfront payment of $190M represents 8.3% of the $2.3B total deal value. For a Phase 1 asset, this ratio is notable. Across metabolic deal benchmarks tracked by Ambrosia, the median upfront-to-TDV ratio for Phase 1 licenses in metabolic disease has hovered around 6–9% over the past 18 months. This deal sits in the upper half of that range, which tells you Roche/Genentech views HM17321 as a differentiated asset, not a speculative option.

Milestone-Heavy, But Not Hollow

$2.1 billion in milestones — 91.3% of the total deal value — might look like headline inflation to the untrained eye. It is not. The $190M upfront is a real commitment, large enough to fund Hanmi's pipeline and operations for years. When a pharma company writes a check that size for a Phase 1 molecule, they are not hedging — they are building internal organizational momentum around the program. Budget approvals, team allocations, and clinical planning at Roche/Genentech are already underway. The milestones are structured to align payment with value inflection: expect the bulk to be gated on Phase 2 proof-of-concept data, regulatory submissions, and first-in-class or best-in-class commercial thresholds.

Royalties remain undisclosed. For a deal of this magnitude, with an upfront north of $150M and total value above $2B, industry precedent suggests tiered royalties in the low-to-mid double digits on net sales. Sub-10% royalties would be inconsistent with the overall economics and Hanmi's negotiating leverage.

Competitive Context — Why Roche/Genentech and Why HM17321

Roche has been conspicuously absent from the top tier of the metabolic peptide race. While Novo Nordisk, Eli Lilly, Amgen, Viking Therapeutics, and Zealand Pharma have staked out positions across GLP-1, GIP, amylin, and glucagon receptor agonism — solo and in combination — Roche's metabolic portfolio has lacked a marquee next-generation peptide program. The CT-388 (Carmot Therapeutics) acquisition in late 2023 for $2.7B gave Roche a GLP-1/GIP dual agonist, but the competitive landscape has evolved. The market now demands differentiated mechanisms, oral formulations, or multi-agonist profiles that go beyond what first-generation dual agonists offer.

HM17321 fits this gap. Hanmi Pharmaceutical has built a deep franchise around its Long-Acting Peptide/Protein Discovery Platform (LAPSCOVERY), which has produced multiple partnered metabolic assets, including efinopegdutide (previously licensed to MSD). HM17321 represents Hanmi's next iteration — a peptide engineered for a differentiated pharmacological profile in metabolic disease. Specific target and mechanism details disclosed at the time of announcement position HM17321 as a potential competitor to next-generation multi-agonists and potentially complementary to Roche's existing metabolic pipeline.

Timing Drivers

Three dynamics forced Roche's hand:

• Competitive compression: Every major pharma now has at least two metabolic peptide programs in clinical development. Waiting for Phase 2 data on HM17321 would have doubled or tripled the acquisition cost — or lost the asset entirely to a rival bidder.
• Hanmi's leverage: Hanmi has demonstrated willingness to run competitive licensing processes. Their 2024–2025 deal flow across metabolic and oncology assets established a pattern of extracting top-quartile terms. Roche had to pay Phase 1 premium pricing or walk away.
• Market validation: The obesity/metabolic drug market is projected to exceed $150B in annual sales by 2035 (multiple analyst estimates). At that TAM, even a mid-single-digit market share justifies a $2.3B deal value for a differentiated Phase 1 asset.

This was not a casual option buy. Roche/Genentech's BD team made a deliberate decision to pay up front for competitive relevance in the highest-growth therapeutic area in biopharma.

What This Means for Similar Assets

If you are a biotech founder or BD executive sitting on a Phase 1 peptide asset in metabolic disease, the Hanmi Pharmaceutical Roche/Genentech deal terms just recalibrated your valuation expectations. Here is what you should internalize:

Upfront Expectations

$190M upfront for a Phase 1 metabolic peptide is not an outlier — it is the new upper quartile. Across comparable Phase 1 metabolic license deals tracked on Solidus, median upfronts have risen from approximately $40–60M in 2023 to $80–130M in 2025–2026. HM17321's $190M reflects Hanmi's platform track record, competitive process leverage, and the specific differentiation of the asset. If your asset has a credible differentiated mechanism and you run a competitive process, $100M+ upfronts are achievable. If you lack either factor, expect to land in the $40–80M range.

Total Deal Value Benchmarks

$2.3B in TDV for a Phase 1 metabolic peptide places this deal in the top decile. But headline TDV is less instructive than the upfront-to-TDV ratio and the milestone structure. Buyers will agree to large TDV numbers because most milestones are never fully paid out. Focus your negotiation on upfront size, near-term milestone triggers (Phase 2 data readout, first regulatory submission), and royalty tiers — these are the components that translate into actual cash flow.

Royalty Benchmarks

Undisclosed royalties in this deal make direct benchmarking harder, but the deal's overall economics constrain the range. For Phase 1 metabolic peptide licenses with upfronts above $100M, royalty floors are typically 10–12% on net sales, tiering up to 18–20%+ on blockbuster thresholds. If you accept single-digit royalties on a metabolic peptide deal in 2026, you are leaving money on the table. The metabolic deal benchmarks on Ambrosia quantify this range across 120+ comparable transactions.

Bottom line: The metabolic peptide licensing market has structurally repriced. Phase 1 assets with differentiated profiles and credible platforms now command upfronts that would have required Phase 2 data three years ago. This deal is evidence, not an anomaly.

Benchmark Your Next Metabolic Deal

The Hanmi–Roche/Genentech transaction is one data point. To build a defensible negotiation position, you need the full distribution — upfronts, milestones, royalties, and deal structures across Phase 1 through commercial-stage metabolic assets. Benchmark your own metabolic deal against 1,800+ comparable transactions using the Ambrosia calculator. Filter by modality, phase, therapeutic area, and deal type to generate custom comps that hold up in a boardroom.